NTLA — Intellia Therapeutics, Inc.

Summary of Intellia Therapeutics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $605.1 million, down from $861.7 million in 2024.
• Collaboration Revenue: Increased to $23 million in Q4 2025 from $12.9 million in the prior year, driven by the termination of a collaboration with SparingVision and increased reimbursement from Regeneron.
• R&D Expenses: Decreased to $88.7 million from $116.9 million year-over-year, primarily due to reduced employee-related expenses and stock-based compensation.
• G&A Expenses: Slightly increased to $33.1 million from $32.4 million.
• Net Loss: Reduced to $95.8 million from $128.9 million in Q4 2024.

2. Strategic Updates and Business Highlights

• Clinical Trials:
  • lonvo-z: Successfully completed enrollment in the HAELO Phase 3 trial with 80 patients, ahead of schedule. Anticipates top-line data by mid-2026 and plans to submit a BLA in the second half of 2026.
  • nex-z: Enrollment in the MAGNITUDE Phase 3 trial for ATTR amyloidosis was paused due to safety concerns but has resumed for MAGNITUDE-2 after FDA lifted the clinical hold.
• Patient Engagement: High interest in lonvo-z among patients and healthcare providers, with 99% of surveyed patients indicating a willingness to use the treatment if approved.
• Commercial Readiness: Increased engagement with physicians and payers, building out sales and reimbursement teams in preparation for a potential product launch.

3. Forward Guidance and Outlook

• Cash Runway: Current cash balance is expected to fund operations into the second half of 2027, covering key milestones including the launch of lonvo-z and completion of MAGNITUDE-2 enrollment.
• Market Potential: If approved, lonvo-z could significantly change the company’s capital needs, with a potential mid-single-digit market share leading to cash flows that could fully fund operations.

4. Bad News, Challenges, or Points of Concern

• Clinical Holds: The MAGNITUDE and MAGNITUDE-2 trials faced a clinical hold due to elevated liver transaminases in a patient, raising safety concerns. Although the hold has been lifted for MAGNITUDE-2, the resolution for MAGNITUDE remains pending.
• Safety Concerns: The potential for immune-mediated liver reactions in treated patients has been identified, necessitating additional monitoring and intervention strategies.
• Market Competition: The company faces competition from other therapies in the HAE space, particularly as new treatments are developed.

5. Notable Q&A Insights

• FDA Engagement: The FDA has been actively engaged with the company, treating the HAE and ATTR programs as distinct, which may influence the regulatory path forward.
• Commercial Strategy: Discussions with payers indicate a recognition of the unmet need in HAE, with a focus on the long-term cost savings of a one-time therapy versus ongoing treatments.
• Patient Population Considerations: The demographic differences between the patient populations in the PN and CM studies may impact the FDA's assessment and the overall safety profile of the treatments.

Overall, Intellia Therapeutics is navigating significant clinical and regulatory challenges while preparing for potential commercial success with its lead gene-editing therapies.